Navellier & Associates Inc Gilead Sciences, Inc. Transaction History

Navellier & Associates Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 05, 2021	SELL	$56.65 - $64.55 $1.09 Million - $1.24 Million	-19,196 Closed	0 $0
Q3 2020 Nov 09, 2020	SELL	$62.1 - $78.08 $2.38 Million - $3 Million	-38,379 Reduced 66.66%	19,196 $1.21 Million
Q2 2020 Aug 12, 2020	BUY	$72.34 - $84.0 $1.49 Million - $1.72 Million	20,531 Added 55.42%	57,575 $4.43 Million
Q1 2020 May 13, 2020	BUY	$62.63 - $80.22 $2.32 Million - $2.97 Million	37,044 New	37,044 $2.77 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Navellier & Associates Inc with notifications on news.